Full Press Release Details
Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
insulin suppository represents an important development in the treatment
diabetes as it provides a painless alternative for effective insulin delivery
Israel - October 23, 2008 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB;
developer of alternative drug delivery systems, announced today that it has
received approval from the South Africa Medicines Control Council (MCC) to
conducting Phase 1A trials on eight healthy human volunteers for ORMD 0802,
company's newly developed insulin suppository.
Phase 1A trials on its insulin suppository mark an important step in the history
of insulin delivery as it will provide a painless option for diabetics who
an alternative to current delivery methods. An insulin suppository is especially
important for small children and seniors, who often struggle with
Phase 1A trial of our insulin suppository is a natural expansion of Oramed's
pursuit and development of alternative insulin delivery systems," said Oramed's
CEO, Nadav Kidron. "By creating an insulin suppository, Oramed hopes to ensure
that diabetics will be able to receive insulin in the form which is most
suitable to their lifestyle and/or age."
Phase 1A trial follows Oramed's announcement of its successful Phase 2A clinical
trials on its oral insulin capsule, ORMD 0801, which demonstrated that the
product has a strong safety profile and was well tolerated, as well as being
effective in lowering blood glucose levels, in patients with type 2
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking
to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed's technology is based on over 25 years of
research by top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in Jerusalem.
more information, please visit www.oramed.com
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements.
and Investor Relation Contacts:
Finn Israel for Oramed